Canopy Growth (CGC) Liabilities and Shareholders Equity (2017 - 2025)
Canopy Growth's (CGC) quarterly Liabilities and Shareholders Equity came in at $793.2 million in Q4 2025, up 71.31% year-on-year from $463.0 million in Q4 2024, and up 2.04% quarter-over-quarter from $777.4 million in Q3 2025.
Canopy Growth (CGC) Liabilities and Shareholders Equity (2017 - 2025) Analysis & Trends
Canopy Growth has disclosed Liabilities and Shareholders Equity across 9 years of filings, most recently posting $793.2 million for Q4 2025.
- Liabilities and Shareholders Equity for Q4 2025 came in at $793.2 million, up 71.31% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.9 billion (down 12.49% YoY), and the FY2025 annual result was $639.6 million, down 33.72% from the prior year.
- Liabilities and Shareholders Equity came in at $793.2 million for Q4 2025 at Canopy Growth, up from $777.4 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $5.7 billion in Q2 2021 to a low of $463.0 million in Q4 2024.
- The 5-year median for Liabilities and Shareholders Equity is $1.4 billion (2023), against an average of $2.2 billion.
- Across the five-year window, Liabilities and Shareholders Equity tumbled 59.22% in 2023 and jumped 71.31% in 2025, its largest moves.
- Canopy Growth's Liabilities and Shareholders Equity stood at $5.0 billion in 2021, then slumped by 56.73% to $2.2 billion in 2022, then tumbled by 53.88% to $998.8 million in 2023, then tumbled by 53.64% to $463.0 million in 2024, then surged by 71.31% to $793.2 million in 2025.
- The last three Liabilities and Shareholders Equity figures came in at $793.2 million (Q4 2025), $777.4 million (Q3 2025), and $652.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 40.04 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 15.15 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 6.71 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 555.95 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 4.91 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 13.22 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.26 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 2.27 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 2.35 Bn |
| 10 | Canopy Growth | 11.38 Mn | -137.31 Mn | 15.39 Mn | 793.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 793.24 Mn |
| Sep 30, 2025 | 777.38 Mn |
| Jun 30, 2025 | 652.91 Mn |
| Mar 31, 2025 | 639.56 Mn |
| Dec 31, 2024 | 463.04 Mn |
| Sep 30, 2024 | 903.38 Mn |
| Jun 30, 2024 | 940.41 Mn |
| Mar 31, 2024 | 964.99 Mn |
| Dec 31, 2023 | 998.79 Mn |
| Sep 30, 2023 | 1.24 Bn |
| Jun 30, 2023 | 1.63 Bn |
| Mar 31, 2023 | 1.80 Bn |
| Dec 31, 2022 | 2.17 Bn |
| Sep 30, 2022 | 2.55 Bn |
| Jun 30, 2022 | 2.75 Bn |
| Mar 31, 2022 | 4.43 Bn |
| Dec 31, 2021 | 5.01 Bn |
| Sep 30, 2021 | 5.16 Bn |
| Jun 30, 2021 | 5.67 Bn |
| Mar 31, 2021 | 5.39 Bn |